Open AccessAD Informer Set: Chemical tools to facilitate Alzheimer's disease drug discovery
Author(s) -
Potjewyd Frances M.,
AnnorGyamfi Joel K.,
Aubé Jeffrey,
Chu Shaoyou,
Conlon Ivie L.,
Frankowski Kevin J.,
Guduru Shiva K. R.,
Hardy Brian P.,
Hopkins Megan D.,
Kinoshita Chizuru,
Kireev Dmitri B.,
Mason Emily R.,
Moerk Charles T.,
Nwogbo Felix,
Pearce Kenneth H.,
Richardson Timothy I.,
Rogers David A.,
Soni Disha M.,
Stashko Michael,
Wang Xiaodong,
Wells Carrow,
Willson Timothy M.,
Frye Stephen V.,
Young Jessica E.,
Axtman Alison D.
Publication year - 2022
Publication title -
alzheimer's and dementia: translational research and clinical interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.49
H-Index - 30
ISSN - 2352-8737
DOI - 10.1002/trc2.12246
Subject(s) - drug discovery , set (abstract data type) , general partnership , disease , computer science , alzheimer's disease , computational biology , portfolio , small molecule , drug development , bioinformatics , data science , medicine , drug , biology , pharmacology , genetics , pathology , finance , financial economics , economics , programming language
The portfolio of novel targets to treat Alzheimer's disease (AD) has been enriched by the Accelerating Medicines Partnership Program for Alzheimer's Disease (AMP AD) program. Methods Publicly available resources, such as literature and databases, enabled a data‐driven effort to identify existing small molecule modulators for many protein products expressed by the genes nominated by AMP AD and suitable positive control compounds to be included in the set. Compounds contained within the set were manually selected and annotated with associated published, predicted, and/or experimental data. Results We built an annotated set of 171 small molecule modulators targeting 98 unique proteins that have been nominated by AMP AD consortium members as novel targets for the treatment of AD. The majority of compounds included in the set are inhibitors. These small molecules vary in their quality and should be considered chemical tools that can be used in efforts to validate therapeutic hypotheses, but which will require further optimization. A physical copy of the AD Informer Set can be requested on the Target Enablement to Accelerate Therapy Development for Alzheimer's Disease (TREAT‐AD) website. Discussion Small molecules that enable target validation are important tools for the translation of novel hypotheses into viable therapeutic strategies for AD.